Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 94

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 94
---
REATING HEMOCHROMATOSIS, AND OTHER DISORDERS |

| 53 |

On March 3, 2025, TELI entered into an exclusive licensing agreement with MIRALOGX LLC, a Florida limited liability company, for the licensing by MIRALOGX to TELI the rights to commercially develop Telomir-1, or the Licensed Products, in all countries outside of the U.S. in which Patent Rights (as defined below) exist (the “Licensing Agreement”). Under the Licensing Agreement, beginning in the calendar year during which revenue is first received by TELI for the Licensed Products, TELI will pay MIRALOGX a minimum annual royalty of two hundred fifty thousand dollars ($250,000). In the event the earned royalty in any calendar year exceeds the minimum royalty payment due for that calendar year, the excess amount shall be credited to any deficiency in the minimum annual royalty payment due in subsequent years. Payment of unearned royalty in any given year shall be credited to earned royalty in any subsequent year. Additionally, TELI also agrees to pay MIRALOGX an amount equal to eight percent (8.0%) of the consideration actually received by TELI for the Licensed Products (the “Net Sales Price”) and total revenue (less the Net Sales Price). Under the Licensing Agreement, TELI is permitted to sublicense the Licensed Products to third parties for an 8% fee on all revenue earned from such sublicensee. The Licensing Agreement expires upon the expiration of the later of the Licensed Products Patent Rights and the date of expiration of the last strategic partnership/sublicensing agreement covering the Licensed Products. TELI may terminate the Licensed Products Licensing Agreement at any time upon thirty (30) days prior written notice to MIRALOGX. The full text of the Licensing Agreement is attached as Annex E to this proxy statement.

The royalties shall continue on a product-by-product basis until the later expiration date of the last expired patent covering the licensed product or the expiration date of the last strategic partnership or sublicensing agreement covering the licensed product.

Besides relying on patents, we also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent protection is appropriate or can be obtained. We seek protection of these trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements. However, these agreements may not provide meaningful protection for, or adequate remedies